NCT04454567View on ClinicalTrials.gov

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

April 8, 2021

Study Completion Date

April 8, 2021

Conditions
Chronic Hepatitis B
Interventions
DRUG

ABI-H0731

Participants will receive ABI-H0731 tablets orally once daily

DRUG

Placebo

Participants will receive placebo to ABI-H0731 tablets orally once daily

DRUG

NrtI

Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert

Trial Locations (12)

1010

Auckland Clinical Studies, Grafton

11030

Northwell Health, Manhasset

19107

Office of X.M., MD, Philadelphia

21201

Institute of Human Virology, Baltimore

33136

Schiff Center for Liver Disease, Miami

90057

Asia Pacific Liver Center, Los Angeles

91105

California Liver Research Institute, Pasadena

92115

Research and Education, San Diego

94115

Quest Clinical Research, San Francisco

08844

Infectious Disease Care, Hillsborough

Unknown

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

Sponsors
All Listed Sponsors
lead

Assembly Biosciences

INDUSTRY

NCT04454567 - A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors | Biotech Hunter | Biotech Hunter